STAT+: Pharmalittle: We’re reading about an FDA official’s speech, a Grail cancer blood test, and much more

In her first address to FDA staff, the top drug regulator at the FDA, Høeg, announced plans to scrutinize the safety of selective serotonin reuptake inhibitors (SSRIs) during pregnancy and the administration of respiratory syncytial virus (RSV) shots to infants. This focus indicates a potential shift in the FDA's approach to evaluating the risks associated with commonly prescribed drugs and vaccines for vulnerable populations, particularly pregnant individuals and infants (Stat News). The scrutiny of SSRIs in pregnancy is significant, as these medications are widely used to treat depression and anxiety disorders in expectant mothers. Concerns regarding the implications of SSRIs on fetal development and maternal health have been a topic of ongoing research and debate within the medical community. Høeg's address emphasizes the FDA's commitment to ensuring that the health and safety of patients are prioritized in the regulatory process (Stat News). Additionally, the emphasis on RSV shots for infants reflects the FDA's role in overseeing vaccines that protect against serious respiratory infections in young children. The RSV vaccine is crucial for preventing severe illness in infants, and Høeg's commitment to examining its safety underscores the importance of rigorous evaluation in the context of pediatric health (Stat News). Overall, Høeg's statements signal a proactive approach to drug safety and efficacy at the FDA.